Haleos Labs Limited (NSE:HALEOSLABS)

Market Cap	4.33B -0.2%
Revenue (ttm)	3.36B -2.5%
Net Income	173.12M -13.9%
EPS	57.26 -13.9%
Shares Out	3.02M
PE Ratio	25.00
Forward PE	n/a
Dividend	1.50 (0.10%)
Ex-Dividend Date	Sep 24, 2025

Volume	1,443
Open	1,499.10
Previous Close	1,443.90
Day's Range	1,401.00 - 1,499.10
52-Week Range	1,067.00 - 1,774.00
Beta	0.32
Analysts	n/a
Price Target	n/a
Earnings Date	May 29, 2026

About Haleos Labs

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesci...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 592
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: HALEOSLABS

Financial Performance

In fiscal year 2026, Haleos Labs's revenue was 3.36 billion, a decrease of -2.46% compared to the previous year's 3.45 billion. Earnings were 173.12 million, a decrease of -13.91%.